Autres langues OliX Pharmaceuticals, Inc

Actions

A226950

KR7226950004

Recherche biotechnologique et médicale

Cours en clôture Korea S.E. 11/09/2026			Varia. 5j.	Varia. 1 janv.
109 300,00 ^KRW	+9,52%		+19,06%	-22,15%

14/08	OliX Pharmaceuticals, Inc publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
30/07	OliX Pharmaceuticals, Inc. publie des données précliniques démontrant une réduction supérieure de la graisse viscérale avec l'OLX501A par rapport à un comparateur mondial chez des primates non humains obèses	CI

Autres langues

14/08	OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
30/07	OliX Pharmaceuticals, Inc Reports Preclinical Data Demonstrating Greater Visceral Fat Reduction with Olx501a Versus Global Comparator in Obese Non-Human Primates
08/07	OliX Pharmaceuticals, Inc announced that it has received KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development
29/06	OliX Pharmaceuticals, Inc announced that it expects to receive KRW 10.526832833 billion in funding from Business Opportunities for L'Oréal Development
04/06	OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP
04/06	OliX Pharmaceuticals Secures KRW 110 Billion Investment from BOLD, L'Oreal Corporate Venture Capital Fund, and Weiss, U.S. Hedge Fund
01/06	OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP
15/05	OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026
01/04	Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office
16/03	OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025
08/02	Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals
02/12	Olix Pharmaceuticals receives milestone payment from L'Oréal
14/11	OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
28/08/25	OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors
14/08/25	OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
15/05/25	OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025
21/03/25	OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2024
10/02/25	Lilly, South Korean Drug Maker Partnering to Commercialize Prospective Liver Disease Treatment
10/02/25	OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
10/02/25	OliX Pharmaceuticals, Inc. and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
14/11/24	OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
09/08/24	Dry Age-related Macular Degeneration Drugs Pipeline 2024 \| Belite Bio, Inflammx Therapeutics, Ocugen, OliX Pharmaceuticals, Gensight Biologics, Alkeus Pharmaceuticals, Dobecure, Cognition Therapeutics
22/03/24	OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors
20/03/24	OliX Pharmaceuticals, Inc announced that it expects to receive KRW 14.7 billion in funding from a group of investors
22/12/23	OliX Pharmaceuticals, Inc Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug